Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > 7M Bid at 1.5c - WHY?
View:
Post by BYLowSELHIGH on Apr 21, 2020 11:36am

7M Bid at 1.5c - WHY?

I have been wondering, WHY so many buyers at bid?

Somthing interesting may happen any time... 

help me what you know, i will the eat the ask!
Comment by 011Peking on Apr 21, 2020 12:11pm
Ya. Same thoughts here!!!  7M!!! =/ what's up people??
Comment by Looking4Doubles on Apr 21, 2020 1:37pm
That's about the amount shorted since March 1st, to keep the price down.  SOMEONE needs to cover (NOT going to happen !) Recent Shorting Activity
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities